The Effect of Levetiracetam Compared with Enzyme-Inducing Antiseizure Medications on Apixaban and Rivaroxaban Peak Plasma Concentrations-Reference-Cited by-同舟云学术

The Effect of Levetiracetam Compared with Enzyme-Inducing Antiseizure Medications on Apixaban and Rivaroxaban Peak Plasma Concentrations

Published:2024-03-23 Issue:5 Volume:38 Page:399-408
ISSN:1172-7047
Container-title:CNS Drugs
language:en
Short-container-title:CNS Drugs

Author:

Goldstein Rachel,Rabkin Natalie,Buchman Noa,Jacobs Aviya R.,Sandouka Khaled,Raccah Bruria,Fisher Negev Tamar,Matok Ilan,Bialer Meir^ORCID,Muszkat Mordechai

Funder

Ministry of Justice IL

Hebrew University of Jerusalem

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40263-024-01077-0.pdf

Reference37 articles.

1. Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Perucca E, et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurol. 2018;17:530–8.

2. Nevitt SJ, Sudell M, Cividini S, Marson AG, Tudur SC. Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data. Cochrane Database Syst Rev. 2022;14(4):CD011412.

3. US Food and Drug Administration. Keppra prescribing information. 2020. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021035s104,021505s044lbl.(pdf. Accessed 25 Jun 2023.

4. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383:955–62.

5. Zeng S, Zheng Y, Jiang J, Ma J, Zhu W, Cai X. Effectiveness and safety of DOACs vs. warfarin in patients with atrial fibrillation and frailty: a systematic review and meta-analysis. Front Cardiovasc Med. 2022;9:907197.